Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation

Clinical Infectious Diseases

Volumn 28, Issue 2, 1999, Pages 322-330

  Ribaud, Patricia ^a,b   Chastang, Claude ^a   Latgé, Jean Paul ^a   Baffroy Lafitte, Laurence ^a   Parquet, Nathalie ^a   Devergie, Agnès ^a   Espérou, Hélène ^a   Sélimi, Fadhéla ^a   Rocha, Vanderson ^a   Derouin, Francis ^a   Socié, Gérard ^a   Gluckman, Eliane ^a  

^a Laboratoire de Mycologie Parasitologie   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BRAIN INFECTION; CHILD; FEMALE; GRAFT SURVIVAL; GRANULOCYTE; HUMAN; LUNG ALVEOLUS MACROPHAGE; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0032971423     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515116     Document Type: Article

References (26)

1. 1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
2. 2. Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996;15:139-45.
3. 3. Ribaud P, Devergie A, Espérou H, et al. Clinical manifestations and therapeutic aspects of deep fungal infections. In: Allogeneic bone marrow transplantation. Proceedings of the 16th International Congress of Chemotherapy (Jerusalem). Jerusalem: E. Lewin-Epstein, 1989:532.1-.2.
4. 4. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impacts of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994;12:827-34.
5. 5. Wingard JR, Beals SU, Santos GW, et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987;2: 175-81.
6. 6. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
7. 7. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. J Clin Invest 1982;69:617-31.
8. 8. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
9. 9. Pannuti C, Gingrich R, Pfaller MA, et al. Nosocomial pneumonia in patients having bone marrow transplant. Cancer 1991;69:2653-62.
10. 10. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
11. 11. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497-503.
12. 12. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
13. 13. Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992;71:24-43.
14. 14. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
15. 15. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Am J Med 1987;83:709-18.
16. 16. Cohen J. Clinical manifestations and management of aspergillosis in the compromised patient. In: Warnock DW, Richardson MD, eds. Fungal infection in the compromised patient. Chichester, United Kingdom: John Wiley & Sons, 1991:117-51.
17. 17. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
18. 18. Einsele H, Hebart H, Löffler H, et al. PCR monitoring of BAL samples to identify patients at risk to develop invasive aspergillosis [abstract no 0334]. Bone Marrow Transplant 1997;19(suppl 1):S84.
19. 19. Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5: 1985-93.
20. 20. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma Interferon. J Clin Invest 1985;76:1755-64.
21. 21. Roilides E, Uhlig K, Venzon D, et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte - induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:4870-7.
22. 22. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994;140:2475-9.
23. 23. Paliogianni F, Raptis A, Ahuja SS, et al. Negative transcription regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993;91:1481-9.
24. 24. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Cambridge, Massachusetts. Blackwell Scientific Publications, 1994:339-62.
25. 25. Ribaud P, Chastang CI, Latgé JP, et al. Invasive aspergillosis (IA) after allogeneic marrow transplantation: survival, prognostic factors and molecular epidemiology in 27 cases observed in a single center [abstract no 843]. Blood 1995;86(suppl 1):214a.
26. 26. Fleming R, Anaissie E, Giralt S, et al. PBSC does not protect against aspergillosis in allogeneic transplantation: a case control study of risk and prognosis factors [abstract no 2429]. Blood 1997;90(suppl 1):545a.